Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.2.421

Negative HER2/neu Amplification Using Immunohistochemistry and Chromogenic in Situ Hybridization Techniques in Skin Melanoma Cases  

Shayanfar, Nasrin (Oncopathology Research Center, Iran University of Medical Sciences)
Bahari, Leila (Department of Pathology, Iran University of Medical Sciences)
Safaie-Naraghi, Zahra (Department of Pathology, Razi Hospital, Tehran University of Medical Sciences)
Kamyab, Kambiz (Department of Pathology, Razi Hospital, Tehran University of Medical Sciences)
Gheytanchi, Elmira (Oncopathology Research Center, Iran University of Medical Sciences)
Rezaei, Nima (Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.2, 2015 , pp. 421-425 More about this Journal
Abstract
Background: This study was performed to evaluate the amplification of HER-2/neu in patients with melanoma. Materials and Methods: Amplification of HER-2/neu was evaluated in a group of patients with melanoma, referred to two referral centers in Tehran, using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) techniques. Results: Forty patients with mean age $57.9{\pm}19.5years$ were enrolled in this study. The most frequent type of melanoma was acral, while lower limbs were the most frequent sites. The amplification of HER2/neu was negative in 97.5% of patients with IHC and in 100% of patients with CISH technique. Only one case (2.5%) shows weak positive staining (+2) in IHC method. Fifty five percent of melanoma was ulcerative, and the most common stages of tumors were stages 4b and 3b. More than 47% of cases were in Clark level III, while the mean of Breslow thickness was $3.56{\pm}2.87mm$. The stage of the case that showed weakly positive staining (2+) in IHC was 4b. Conclusions: The amplification of HER2/neu biomarker was negative in patients with melanoma, using both CISH and IHC techniques.
Keywords
Melanoma; HER2/neu; amplification; IHC; CISH;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Yu D, Wang SS, Dulski KM, et al (1994). c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res, 54, 3260-6.
2 Allgayer H, R. Babic, et al (2000). c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol, 18, 2201-9.
3 Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O (2003). Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol, 16, 1035-40.   DOI
4 Bodey B, Bodey Jr B, Groger AM, et al (1997). Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res, 17, 1319-30.
5 Chenevix-Trench G, Martin NG, Ellem KA et al (1990). Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53. Oncogene, 5, 1187-93.
6 Cihan YB, Baykan H, Kavuncuoglu E, et al (2013). Relationships between skin cancers and blood groups--link between nonmelanomas and ABO/Rh factors. Asian Pac J Cancer Prev, 14, 4199-4203.   DOI   ScienceOn
7 Demierre MF, Chung C, Miller DR, Geller AC (2005). Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol, 141, 745-50.
8 Easty DJ, Herlyn M, Bennett DC (1995). Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer, 60, 129-36.   DOI
9 El-Sheikh S, El-Sheikh S, El-Morsy I (2009). Detection of c-Kit (CD117) and HER-2/neu in Oral and Cutaneous Malignant Melanomas. J Egypt Women DermatolSoc, 6, 66-73.
10 Gershenson DM, Tortolero-Luna G, Malpica A, et al (1996). Ovarian intraepithelial neoplasia and ovarian cancer. Obstet Gynecol Clin North Am, 23, 475-543.
11 Gheytanchi E, Mehrazma M, Madjd M (2014). Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma. Asian Pac J Cancer Prev, 15, 3065-70.   DOI   ScienceOn
12 Gleeson G, Larkin A, Horgan N, Kennedy S (2014). Evaluation of chromogenic in situ hybridization for the determination of monosomy 3 in uveal melanoma. Arch Pathol Lab Med, 138, 664-70.   DOI
13 Hetzel DJ, Wilson TO, Keeney GL, et al (1992). HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol, 47, 179-85.   DOI
14 Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN (1993). Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol, 16, 93-104.   DOI
15 Hoersch B, Leiter U, Garbe C (2006). Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol, 155, 771-7.   DOI
16 Krahn G, Leiter U, Kaskel P, et al (2001). Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer, 37, 251-9.
17 Hwang CC, Pintye M,Chang LC, et al (2011). Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. Histopathology, 59, 984-92.   DOI
18 Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ (2000). Early detection and treatment of skin cancer. Am Fam Physician, 62, 357-68.
19 Kanavy HE, Gerstenblith MR (2011). Ultraviolet radiation and melanoma. Semin Cutan Med Surg, 30, 222-8.   DOI
20 Lens MB, Dawes M (2004). Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol, 150, 179-85.   DOI   ScienceOn
21 Levi F, Randimbison L, La Vecchia C, Te VC, Franceschi S (1998). Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int J Cancer, 78, 315-19.   DOI
22 Mayr D, Heim S, Weyrauch K, et al (2009). Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology, 55, 716-23.   DOI
23 Narin A, Tuncay O (2012). Relationships between malignant melanoma and chromosome damage in human peripheral blood lymphocytes. Asian Pac J Cancer Prev, 13, 5229-32.   DOI   ScienceOn
24 Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.   DOI
25 Potti A, Moazzam N, Langness E, et al (2004). Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol, 130, 80-6.   DOI
26 Pauletti G, Godolphin W, Press MF, Slamon DJ (1996). Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene, 13, 63-72.
27 Persons DL, Arber DA, Sosman JA, Borelli KA, Slovak ML (2000). Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. Anticancer Res, 20, 1965-8.
28 Potti A, Hille R, Koch M (2003). Immunohistochemical determination of HER-2/neu in malignant melanoma. Anticancer Res, 23, 4067-9.
29 Rongcun Y, Salazar-Onfray F, Charo J, et al (1999). Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol, 163, 1037-44.
30 Safaie-Naraghi Z, Bahadori M, Ehsani AH, et al (2006). Evaluation of primary cutaneous malignant melanoma according to Breslow and Clarke pathological indices. Tehran University Medical Journal, 64, 79-85.
31 Tanner M, Gancberg D, Di Leo A, et al (2000). Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol, 157, 1467-72.   DOI
32 Tsugawa K, Fushida S, Yonemura Y (1993). Amplification of the c-erbB-2 gene in gastric carcinoma: correlation with survival. Oncology, 50, 418-25.   DOI
33 Ullrich A, Schlessinger J (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203-12.   DOI